Sunday 11 October 2026 Export all VXRT data to Excel Powerpack

VAXART, INC.

VXRT Healthcare Biotechnology

VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024. In the quarter to June 2026, revenue fell 31.6%, EPS grew 14.3% and free cash flow grew 117.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

0.43 0.00 0.00%
Market cap
$92.4M
P/E
2.8×
Fwd P/E
2.1×
Dividend yield
—
F-score
6/9
Altman Z
−1.06
Beneish M
3.73
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
3.81 4.07 5.83 0.00

+8 more quarters

P/S ratio
0.61 0.57 0.34 0.56
P/FCF ratio
4.42 9.92 10.64 0.00
P/Operating CF
53.18 (71.47) 2.63 31.76
P/B ratio
1.79 1.56 0.92 3.08
EV/Sales
0.35 0.34 0.08 0.37
EV/EBITDA
1.87 1.91 0.68 0.00
EV/FCF
2.54 5.87 2.37 (1.80)
Current Ratio
1.60 1.71 1.57 0.69
Net Debt/EBITDA
5.11 (9.77) (1.12) 5.17
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
26.23% 24.59% 17.14% (63.89%)
Free Cash Flow Yield
22.61% 10.08% 9.40% (36.98%)
Free Cash Flow per Share
0.01 (0.01) 0.13 0.01
Book value per Share
0.34 0.39 0.38 0.12
Free Cash Flow
2.75 (2.50) 30.66 2.48
EV/EBIT
2.14 2.28 0.99 0.00
Other line items

Show all line items

Columns are period end dates